The triage followed the European Society for Medical Oncology guidelines that recommend giving high priority to the systemic treatment of early‐stage breast cancer in the following cases: chemotherapy for triple negative, HER2‐positive, high‐risk hormone receptor‐positive HER2‐negative breast cancers, and NAC that has already been started.21 This evidence concerns the gene ERBB2 and breast cancer.